Is Our Approach to Renal (Kidney) Cell Cancer Changing? 3 Important ESMO Studies

The most common adult kidney cancer is renal cell carcinoma. Surgery is the primary treatment. No proven postoperative preventive option existed in early disease, while targeted treatments significantly extended advanced-disease survival.
At ESMO 2016, 3 important studies in this field were presented; let us examine them together:
Study-1
In disease spreading to other organs (metastatic) renal cell carcinoma, first-line sunitinib is our standard treatment. It inhibits intracellular growth and proliferation signaling called tyrosine kinase in the inner cell membrane. To determine whether new drugs could outperform this standard, researchers compared sunitinib with the targeted medicine cabozantinib , a multireceptor inhibitor also blocking receptors involved in tumor resistance.
This phase-II trial included metastatic (stage 4) patients, 80 in total. Cabozantinib outperformed Sunitinib, adding 3 months of disease control and yielding 30 months overall survival. These are the best survival results in stage 4 renal cell cancer. Promising but insufficient to change routine practice, they await larger phase-III results. Similar success there would substantially alter oncology practice.
Study 2
Another study tested postoperative prevention in early nonmetastatic kidney cancer. Previous research had proven no recurrence-reducing benefit after surgery, so we observe without additional treatment. The first of two studies asking aboutadjuvantbenefit showed that high-risk patients taking sunitinib for 1 year gained longer time after treatment before recurrence (at 5 years, an %8 benefit), compared with no treatment. Presented at the congress and simultaneously published in New England Journal of Medicine, the study continues follow-up, so overall survival results are not yet published.
Study 3
Despite that positive result, another early-stage postoperative study found no benefit from sunitinib or sorafenib.
Thus, one positive and one negative study address postoperative preventive chemotherapy. Overall survival analyses are needed before changing practice.
Conclusion
Though not yet standard, these three studies offer hope for better outcomes with new-generation treatments.
Sources
ESMO 2016, Abstract LBA30_PR.
2- Alain Ravaud, M.D., Ph.D., Robert J. Motzer, M.D., Hardev S. Pandha, M.D., Ph.D. et al.
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
October 10, 2016DOI: 10.1056/NEJMoa1611406
Was this article helpful?
Your feedback helps us improve our content.




Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.